Flurizan - CAS 51543-40-9
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Flurizan, also called Tarenflurbil, is a nonsteroidal anti-inflammatory drug which inhibits γ-secretase activity leading to preventing the formation of the amyloid β peptide (Aβ42) from amyloid β precursor protein (APP).
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
Reduces Aβ42 levels (Amyloid-β: IC50 = 280 µM (human); γ-secretase inhibitor
White solid
(2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid; 257-264-7; 501W00OOWA; flurizan; MPC-7869; MPC7869; tarenflurbil; Tarenflurbil; (R)-Flurbiprofen; Flurizan; R-Flurbiprofen; 51543-40-9; (R)-2-Flurbiprofen; MPC-7869; (2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid; (R)-2-Flubiprofen; (2r)-2-(3-Fluoro-4-Phenyl-Phenyl)propanoic Acid; UNII-501W00OOWA; (-)-(2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid; CHEMBL190083; CHEBI:38666; (2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid; E-7869; (R)-(-)-2-Fluoro-alpha-methyl-4-biphenylacetic acid; (R)-2-Fluoro-alpha-methyl(1,1'-biphenyl)-4-acetic acid; Flurwood; (2R)-2-(2-fluoro-[1,1'-biphenyl-4-yl])propanoic acid; Urbifen, Ansaid, Flurwood, Froben, Flurbiprofen; Furbiprofen; TruNoc; NSC685699; NCGC00016654-01; (-)-Flurbiprofen; FLP; CAS-5104-49-4; S1679_Selleck; Tocris-1769;
Soluble to 49 mM at 25ºC in DMSO, to 49 mM at 25ºC in ethanol, to <1 mM at 25ºC in water, to ~25 mM in DMF, and to ~0.9 mM in PBS (pH 7.2).
Store in a cool and dry place and at 0 - 4℃ for short term (days to weeks) or -31℃ for long term (months to years).
Boiling Point:
162.4℃ at 760 mmHg
Melting Point:
1.555 g/cm3
Canonical SMILES:
Current Developer:
1.Generalized model of electromigration with 1:1 (analyte:selector) complexation stoichiometry: part II. Application to dual systems and experimental verification.
Müllerová L1, Dubský P2, Gaš B1. J Chromatogr A. 2015 Mar 6;1384:147-54. doi: 10.1016/j.chroma.2015.01.055. Epub 2015 Jan 23.
Interactions among analyte forms that undergo simultaneous dissociation/protonation and complexation with multiple selectors take the shape of a highly interconnected multi-equilibrium scheme. This makes it difficult to express the effective mobility of the analyte in these systems, which are often encountered in electrophoretical separations, unless a generalized model is introduced. In the first part of this series, we presented the theory of electromigration of a multivalent weakly acidic/basic/amphoteric analyte undergoing complexation with a mixture of an arbitrary number of selectors. In this work we demonstrate the validity of this concept experimentally. The theory leads to three useful perspectives, each of which is closely related to the one originally formulated for simpler systems. If pH, IS and the selector mixture composition are all kept constant, the system is treated as if only a single analyte form interacted with a single selector.
2.Novel flurbiprofen derivatives with improved brain delivery: synthesis, in vitro and in vivo evaluations.
Zheng D1, Shuai X, Li Y, Zhou P, Gong T, Sun X, Zhang Z. Drug Deliv. 2015 Jul 21:1-10. [Epub ahead of print]
Tarenflurbil (R-flurbiprofen) was acknowledged as a promising candidate in Alzheimer's disease (AD) therapy. However, the Phase III study of tarenflurbil was extremely restricted by its poor delivery efficiency to the brain. To tackle this problem, the novel carriers for tarenflurbil, racemic flurbiprofen (FLU) derivatives (FLU-D1 and FLU-D2) modified by N,N-dimethylethanolamine-related structures were synthesized and characterized. These derivatives showed good safety level in vitro and they possessed much higher cellular uptake efficiency in brain endothelial cells than FLU did. More importantly, the uptake experiments suggested that they were internalized via active transport mechanisms. Biodistribution studies in rats also illustrated a remarkably enhanced accumulation of these derivatives in the brain. FLU-D2, the ester linkage form of these derivatives, achieved a higher brain-targeting efficiency. Its Cmax and AUC0-t were enhanced by 12.
3.γ-Secretase modulator in Alzheimer's disease: shifting the end.
Xia W1, Wong ST, Hanlon E, Morin P. J Alzheimers Dis. 2012;31(4):685-96. doi: 10.3233/JAD-2012-120751.
The outcomes of the clinical trials of the γ-secretase inhibitor Semagacestat (LY-450139) and the γ-secretase modulator (GSM) Tarenflurbil were disappointing, but may not represent the end of the γ-secretase era. γ-Secretase modulators, by definition, only block the γ-secretase cleavage of amyloid-β protein precursor (AβPP) to generate the longer, 42-residue amyloid-β (Aβ42) without changing the production of total Aβ. The first generation GSMs were shown to block Aβ42 generation while increasing Aβ38. The non-steroidal anti-inflammatory drug, Tarenflurbil, binds to AβPP and shifts the cleavage site from Aβ42 to Aβ38. In addition, Tarenflurbil does not affect the γ-secretase cleavage of Notch. Even before the failed clinical trials of Tarenflurbil, second generation GSMs had emerged, and some of these GSMs interact with presenilin, which carries the active site of the γ-secretase. While second generation GSMs are pharmacologically superior to first generation GSMs, in vivo Aβ profiles (decreased levels of Aβ38, Aβ40, and Aβ42) in animals treated with potent GSMs are strikingly different from those in cultured cells.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related γ-secretase Products

CAS 62252-26-0 JLK 6

(CAS: 62252-26-0)

JLK 6, under the IUPAC name 7-amino-4-chloro-3-methoxyisochromen-1-one, an inhibitor of γ-secretase (IC50= between 10 μM-1 mM) that belongs to the class of isoc...

TC-E 5006
(CAS: 1257395-14-4)

TC-E 5006, also called BIIB042, a potent γ-secretase modulator, which lowered Aβ42, increased Aβ38, but had little to no effect on Aβ40 levels both in vitro and...

CAS 1172637-87-4 gamma-secretase modulator 1

gamma-secretase modulator 1
(CAS: 1172637-87-4)

gamma-secretase modulator 1 is a gamma-secretase modulator, useful for Alzheimer's disease.

LY-411575 isomer 3

LY-411575 isomer 3, is an isomer of LY411575, which is a potent, cell-permeable γ-secretase inhibitor (IC50= 0.078 nM/0.082 nM (in membrane-assay/in cell-based...

CAS 937812-80-1 gamma-Secretase modulators

gamma-Secretase modulators
(CAS: 937812-80-1)

gamma-Secretase Modulators, as a potent modulator of γ-secretase, it is derived from oxadiazine. IC50: Aβ42=11 nM, Aβtotal/ Aβ42=1170.

CAS 209984-56-5 DBZ

(CAS: 209984-56-5)

DBZ, also called dibenzazepine, is a γ-secretase inhibitor to treat Alzheimer′s Disease, and it also inhibit Notch signaling.

CAS 209984-57-6 LY-411575

(CAS: 209984-57-6)

LY-411575, also known as LSN-411575, is a potent, cell-permeable γ-secretase inhibitor (IC50= 0.078 nM/0.082 nM (in membrane-assay/in cell-basedγ-secretase ass...

CAS 749269-83-8 CHF 5074

CHF 5074
(CAS: 749269-83-8)

CHF5074, also known as CSP-1103, is a novel γ-secretase modulator. It could reduce Aβ42 and Aβ40 secretion, which IC50 value is 3.6 and 18.4 μM respectively. It...

CAS 161710-10-7 Z-Ile-Leu-aldehyde

(CAS: 161710-10-7)

Z-Ile-Leu-aldehyde, also known as Z-IL-CHO or GSI-XII, inhibits γ-secretase and Notch signaling. In vitro: induces apoptosis of murine MOPC315.BM myeloma cells ...

CAS 769169-27-9 Begacestat

(CAS: 769169-27-9)

Begacestat is a selective thiophene sulfonamide inhibitor of amyloid precursor protein γ-secretase. Begacestat inhibits Abeta production with low nanomolar pote...

CAS 870843-42-8 E 2012

E 2012
(CAS: 870843-42-8)

E 2012, is a potent selective, orally bioavailable γ-secretase modulator without affecting Notch processing that can used to treat Alzheimer's Disease.

PF 3084014 hydrobromide

PF 3084014 hydrobromide, developed by Pfizer, is a potent γ-secretase inhibitor (in whole cell: IC50= 1.2 nM; in cell-free assaysand IC50= 6.2 nM).

CAS 1290543-63-3 PF-3084014

(CAS: 1290543-63-3)

PF-3084014, also called Nirogacestat, is a selective γ-secretase inhibitor (IC50= 6.2 nM in a cell-free assay) that was shown by the reduction of endogenous NIC...

CAS 173550-33-9 Compound W

Compound W
(CAS: 173550-33-9)

Compound W, also called 3,5-bis(4-Nitrophenoxy)benzoic acid, a 3,3'-diiodothyronine sulfate cross-reactive substance, is an inhibitor of γ-secretase which cause...

CAS 209984-58-7 LY-411575 isomer 1

LY-411575 isomer 1
(CAS: 209984-58-7)

LY-411575 isomer 1, is an isomer of LY411575, which is a potent, cell-permeable γ-secretase inhibitor (IC50= 0.078 nM/0.082 nM (in membrane-assay/in cell-based...

CAS 677772-84-8 MRK 560

MRK 560
(CAS: 677772-84-8)

MRK 560, under the IUPAC name N-((1r,4r)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)-1,1,1-trifluoromethanesulfonamide, is a novel orally bio...

CAS 1093978-89-2 gamma-secretase modulator 2

gamma-secretase modulator 2
(CAS: 1093978-89-2)

gamma-secretase modulator 2,a triazole derivative, a potent and selective γ-secretase modulator so as to selectively attenuate production of Aβ(1-42) and hence ...

CAS 292632-98-5 L-685,458

(CAS: 292632-98-5)

L-685,458, a transition state analogue inhibitor, as a selective and potent inhibitor of γ-secretase (IC50 = 17 nM) it shows > 50-fold selectivity over a variet...

CAS 1431697-84-5 gamma-secretase modulator 3

gamma-secretase modulator 3
(CAS: 1431697-84-5)

gamma-secretase modulator 3 is a γ-secretase inhibitor.

LY 450139
(CAS: 866488-53-1)

Semagacestat is a gamma-secretase inhibitor originally developed by Eli Lilly. In Aug 2010, Phase-III for Alzheimer's disease was discontinued.

Chemical Structure

CAS 51543-40-9 Flurizan

Quick Inquiry

Verification code

Featured Items